Product logins

Find logins to all Clarivate products below.


Hemanth Nair

Senior Director, Real World Data Analytics

Dr. Hemanth P. Nair is the Senior Director of RWD Analytics Services. Formally trained in epidemiology and population health he has deep experience in data science, visualization, and digital technology. He has over 15 years of successfully leading and delivering advanced analytics and data visualization products and solutions to U.S. corporate and government clients, particularly at the intersection of epidemiology, population health and real-world data. ​

Dr. Nair has held past leadership roles in analytics with PwC, ClearPrism and Booz Allen Hamilton. Prior to that he served as lead scientist with New York City Department of Health’s World Trade Center Health Registry. He began his career as an Epidemic Intelligence Service officer with the Centers for Disease control and prevention, following his PhD training (Neuroscience) at the University of Texas at Austin and Master’s of Public Health (Biostatistics) at Emory University.


arrow_forward
Get in touch with Hemanth

Related resources

应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径 应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
Blog February 24, 2026
应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
前进之路:收到 CRL 后该何去何从? 前进之路:收到 CRL 后该何去何从?
Blog February 24, 2026
前进之路:收到 CRL 后该何去何从?
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
Relacorilant:当证据满足既定证据标准时 Relacorilant:当证据满足既定证据标准时
Blog February 24, 2026
Relacorilant:当证据满足既定证据标准时
FDA 临床试验 市场准入 最值得关注的药物 真实世界数据 美国市场 药政法规
Tolebrutinib:当安全性隐忧掩盖疗效信号 Tolebrutinib:当安全性隐忧掩盖疗效信号
Blog February 24, 2026
Tolebrutinib:当安全性隐忧掩盖疗效信号
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规 药物安全